Surfing the MASH Tsunami
Episodes
S2 E6 - #RealTalk on Clinical Trial Design and Execution
11 Feb 2021
Contributed by Lukas
Send a textNaim Alkhouri and Dr. Rashmee Patil of the South Texas Research Institute join the Surfers to discuss practical challenges and issues in co...
S2 E5.5 - Bonus Interview with Suneil Hosmane: What FDA webcast means for "Wet" Diagnostics
10 Feb 2021
Contributed by Lukas
Send a textNEW CONTENT: Suneil Hosmane joins Roger Green to discuss why he found the FDA Webcast so encouraging for liquid biomarkers.BONUS INTERVIEW:...
S2 E5.4 - Bonus Interview with Prof. Dr. Jörn M. Schattenberg: What FDA webcast means for researchers and trial sites outside the US
10 Feb 2021
Contributed by Lukas
Send a textNEW CONTENT: Prof. Dr. Jörn M. Schattenberg joins Roger Green to discuss his highly optimistic reaction to the FDA Webcast. BONUS INTERVIE...
S2 E5.3 — After the FDA Webcast: Discussing Drug Development and Clinical Trial Strategies
09 Feb 2021
Contributed by Lukas
Send a textThe Surfers and guests Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of the...
S2 E5.2 — After the FDA Webcast: Discussing Clinical Endpoints
09 Feb 2021
Contributed by Lukas
Send a textThe Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of the ...
S2 E5.1 - After the FDA Webcast: Beginning and Ending Perceptions
08 Feb 2021
Contributed by Lukas
Send a textThe Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale share high-level perspec...
S2 E4.2 - Anticipating The FDA Webcast: Specific Items to Listen For
04 Feb 2021
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development.In this c...
S2 E4.1 - Anticipating the FDA Webcast: Overall Areas for Guidance
04 Feb 2021
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development.In this c...
S2 E5 - What We Learned at Today's FDA Webcast on NASH Drug Development
01 Feb 2021
Contributed by Lukas
Send a textManal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday's FDA ...
S2 E4 - What to Listen For Friday at the FDA Webcast
28 Jan 2021
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to share expectations in advance of Friday's FDA Webcast on NASH Drug Development.FDA's Friday...
S2 E3.2 - Call to action: Can We use COVID-19 Vaccine Centers to support Liver health?
23 Jan 2021
Contributed by Lukas
Send a textThe Surfers discuss ways that COVID-19 Vaccine Centers might present an opportunity to educate and screen patients on Liver HealthStephen H...
S2 E3.1 - Challenges Disadvantaged Minorities Face in Liver Health
23 Jan 2021
Contributed by Lukas
Send a textDonna Cryer and Louise Campbell discuss how governmental action (or inaction) couple with community efforts to shape Liver Health initiativ...
S2 E3 A Call to Action on MLK Day: Supporting disadvantaged Minorities in Managing Liver Health
21 Jan 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to explore efforts to support residents in disadvantaged minority communities in the US, UK, and Australia in...
S2 E2.3 - Partners and enablers Necessary to Help Drive Broader NAFLD and Non-Communicable Disease
16 Jan 2021
Contributed by Lukas
Send a textThe Surfers end this episode by discussing the need for public education to create the awareness necessary for change.This conversation cov...
S2 E2.2 - Economic and Patient Motivation Costs and Value of telemedicine and New Non-Invasive Diagnostic Testing
16 Jan 2021
Contributed by Lukas
Send a textEvaluating the economic and patient-motivating value of enhanced telemedicine and mobile non-invasive testing technologies in improving NAF...
S2 E2.1 - Innovations in Telemedicine and Mobile Technology can improve care for NAFLD patients
16 Jan 2021
Contributed by Lukas
Send a textInnovations in Telemedicine and Mobile Technologies are already changing patient care in ways that will remain and expand in the "New ...
S2 E2 — How COVID-19 is changing patient management and clinical trials
14 Jan 2021
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to describe long-term changes in patient management that improved diagnostic and telecommunication techn...
S2 E1.3 - Challenges and Big Ideas for NAFLD/NASH Patient Diagnosis and Treatment in the Post-Second Wave World
09 Jan 2021
Contributed by Lukas
Send a textQuestion: If NALFD patients have poorer COVID-19 prognoses, how can we use this fact to drive broader population-based screening?This conve...
S2 E1.2 Successfully Managing Clinical Trials during COVID-19's Second Wave
09 Jan 2021
Contributed by Lukas
Send a textThe COVID-19 conversation continues with the group focusing on challenges in clinical trial execution and how innovative logistics and cons...
S2 E1.1 - How Recent COVID-19 News Affects NAFLD and NASH Patients
09 Jan 2021
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to consider the three most important COVID-19 stories today.The conversation focuses on the British vari...
S2 E1 - How Will COVID-19 Affect the Fatty Liver Community in 2021?
07 Jan 2021
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to discuss how recent COVID-19 news might affect Fatty Liver patients and what the medical profession an...
44.4 2020 Year In Review: How Patients and Patient Advocates reacted to a year of lows and high
01 Jan 2021
Contributed by Lukas
Send a textWayne Eskridge describes how hope fell and then rose as patients did not receive the drug approval they expected but then learned about exc...
44.3 2020 Year In Review: Revisiting the "MAFLD vs. NAFLD" debate
01 Jan 2021
Contributed by Lukas
Send a textLouise Campbell questions the implication of APASL and ALEH endorsing "MAFLD" as Fatty Liver Disease nomenclature and Stephen Har...
44.2 2020 Year In Review: Fatty Liver Disease Enters the Public Dialogue in Germany
01 Jan 2021
Contributed by Lukas
Send a textJoern Schattenberg discusses the public health implications of German newspapers beginning to discuss Fatty Liver DiseaseFor Joern Schatten...
44.1 2020 Year in Review: Simplifying NASH Diagnostics Saves Money, improves satisfaction
01 Jan 2021
Contributed by Lukas
Send a textIan Rowe discusses how streamlined use of ELF, FIB-4 and FibroScan improves cost effectiveness and patient satisfaction associated with NAS...
2020 Year-End NASH Review 2: Patient Treatment and Perspectives
30 Dec 2020
Contributed by Lukas
Send a textGuests Ian Rowe, Joern Schattenberg and Wayne Eskridge join the Surfers to discuss key lessons learned in 2020 about Patient Treatment and ...
43.4 2020 Year in Review: The Law of Unintended Consequences Blesses NASH Drug Development
25 Dec 2020
Contributed by Lukas
Send a textRoger Green discusses why despite widespread concerns, FDA's Complete Response Letter to Intercept did not cripple progress in NASH dr...
43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals
25 Dec 2020
Contributed by Lukas
Send a textStephen Harrison summarizes a year of progress in improving the tests and analyses used to derive clinical endpoints necessary to initial d...
43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in fatty Liver Disease
25 Dec 2020
Contributed by Lukas
Send a textMazen Noureddin describes a year in which biopsy's shortcomings are revealed at the same time as non-invasive testing becomes better a...
43.1 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics
25 Dec 2020
Contributed by Lukas
Send a textVlad Ratziu discusses a "boiling hot" field of emerging NASH drugs and "particularly rich" data coming from no-invasive...
2020 Year-End NASH Review 1: Drugs and Diagnostics - Ep 43
24 Dec 2020
Contributed by Lukas
Send a textThe Surfers and guests Vlad Ratziu and Mazen Noureddin discuss key lessons learned in 2020 about Drugs and Diagnostics.Vlad Ratziu and Maze...
Policy 2: Credibility, Convergence and the 2021 Global Liver Institute Action Plan - Ep 42
17 Dec 2020
Contributed by Lukas
Send a textDonna Cryer and Global Liver Institute Director of Policy Andrew Scott return to discuss their 2021 US NASH Action Plan, garnering support ...
Policy 1: The Liver Policy Agenda Has Experienced Surprising Success in the Last Four Years - Ep 41
10 Dec 2020
Contributed by Lukas
Send a textDonna Cryer and Global Liver Institute Director of Policy Andrew Scott join Stephen, Louise and Roger to discuss the policy progress liver ...
Links between NAFLD and Cardiovascular Disease - Ep 40
03 Dec 2020
Contributed by Lukas
Send a textDr Ian Rowe and Prof. Dr. Jörn M. Schattenberg joins the Surfers to explore the relationship between NAFLD and CVD in light of recent work...
COVID CHAOS: The 2nd Wave - Ep 39
24 Nov 2020
Contributed by Lukas
Send a textGuest Ian Rowe and Dr. Kris Kowdley join the Surfers to discuss how the 2nd COVID wave and arrival of the vaccine are likely to affect pati...
The Day After TLMdX 2020 Wrapping Up with The View from Across the Atlantic - Ep 38
19 Nov 2020
Contributed by Lukas
Send a textProf. Vlad Ratziu, MD, and Prof. Dr. Jörn M. Schattenberg join the Surfers to wrap up our conversation about this year's AASLD meet...
Day Four of TLMdX 2020 - Monday at the Digital Liver Meeting -- Getting Better at Diagnostics and Drugs, Not Education - Ep 37
17 Nov 2020
Contributed by Lukas
Send a textThe Surfers spend the final day of AASLD 2020 looking at two very different sets of issues. Issue 1: challenges proving efficacy in F2 popu...
Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36
16 Nov 2020
Contributed by Lukas
Send a textReviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs.Naim Alkhouri and Mazen Noured...
Day Two of TLMdX 2020 - Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint - Ep 35
15 Nov 2020
Contributed by Lukas
Send a textManal Abdelmalek joins the Surfers to review some of Saturday's most exciting presentations and posters from AASLD 2020, followed by a...
Why NASH Drug Trials Fail: A Thoughtful, Challenging Theory - Ep 34
12 Nov 2020
Contributed by Lukas
Send a textProf. Dr. Jörn M. Schattenberg joins the Surfers to discuss his recent article in Expert Opinion on Investigational Drugs dissecting recen...
Previewing The Digital Liver Meeting (TLMDx from AASLD): Part Two - Ep 33
05 Nov 2020
Contributed by Lukas
Send a textStephen Harrison, Roger Green and our guest Surfer, Dr. Manal Abdelmalek, identify pivotally important presentations and posters from The D...
Previewing The Digital Liver Meeting (TLMDx from AASLD): Part One - Ep 32
29 Oct 2020
Contributed by Lukas
Send a textLouise Campbell, Donna Cryer, and Naim Alkhouri identify pivotally important presentations and posters from The Digital Liver Meeting 2020....
How Have The Events of 2020 Affected Patient Treatment In The Clinic? Ep 31
22 Oct 2020
Contributed by Lukas
Send a textGuest Surfer and regular listener Dr. Ian Rowe joins the Surfers to discuss how everyday patient treatment in the clinic once was and how C...
Six Months In: How COVID-19 Has Changed Our World!
15 Oct 2020
Contributed by Lukas
Send a textOn the six-month anniversary of SurfingNASH's first episode, the Surfers stop to consider how much has changed for NASH stakeholders s...
COVID-19 and the Liver, “it's complicated - Ep 29
08 Oct 2020
Contributed by Lukas
Send a textMatt Kelly, Chief Innovation Officer at Perspectum, Ltd., joins the Surfers to discuss early findings from the COVERSCAN study which looks ...
Wild Times in NASH-Ville Part 3: Better Days ARE Ahead! Ep 28
01 Oct 2020
Contributed by Lukas
Send a textStephen Harrison leads the Surfers through a review of FGF-21s and other exciting drug development news.Stephen Harrison starts this week&a...
Crystal Ball Tells Us The Most Important Stories Of Autumn - Ep 27
24 Sep 2020
Contributed by Lukas
Send a textThe Surfers discuss four issues that are likely to affect how our thinking about NASH diagnosis, education, and treatment might evolve over...
"Beond the Biopsy" How NASH Therapy Will Improve When Non-Invasive Tests Become The Standard - Ep 26
17 Sep 2020
Contributed by Lukas
Send a textThe Surfers discuss the Global Liver Institute's campaign to educate and motivate key stakeholder groups on the value of non-invasive ...
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
10 Sep 2020
Contributed by Lukas
Send a textThe Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular...
EASL Digital ILC 2020 Wrap-Up: A Complicated Picture Emerges - Ep 24
02 Sep 2020
Contributed by Lukas
Send a textProfessors Joern Shcattenberg and Vlad Ratziu join the Surfers to discuss the lessons and findings we can take away from Digital ILC 2020.W...
Digital ILC Day Three Highlights: Late breakers, COVID and more - Ep 23
29 Aug 2020
Contributed by Lukas
Send a textSurfingNASH's Digital ILC coverage ends with three late-breaking drug presentations, a discussion of EASL's COVID efforts, and in...
Digital ILC Day Two Highlights: A Fork in the Road - Ep 22
28 Aug 2020
Contributed by Lukas
Send a textDrugs in development and diagnostics show promise but healthcare has far to go in identifying and treating patients in need.Professor Vlad ...
Digital ILC Day One Highlights: Much to Think About - Ep 21
28 Aug 2020
Contributed by Lukas
Send a textOne day into the first-ever digital major conference, the Surfers review six presentations and one interactive session. A lot was learned, ...
How will Digital ILC be different from past conferences? - Ep 20
27 Aug 2020
Contributed by Lukas
Send a textThe group discusses the plusses and minuses of digital conferences compared to traditional in-person events.Digital ILC starts Thursday, Au...
What NASH patients want from outside the healthcare system - Ep 19
20 Aug 2020
Contributed by Lukas
Send a textThe second part of the "What NASH patients want" series focuses on the future of healthcare apps and the role government agencies...
What NASH Patients Want From the Healthcare System - Ep 18
13 Aug 2020
Contributed by Lukas
Send a textPatient advocates discuss how doctors and other providers can serve patient needs betterGuest surfer Anthony Villiotti, President of NASH k...
Previewing EASL: Part 2 - Ep 17
06 Aug 2020
Contributed by Lukas
Send a textDonna Cryer, President & CEO of the Global Liver Institute, and Louise Campbell, Founder of Tawazun Health, become Surfing regulars in ...
Nurses Helping NASH Patients - Ep 16
30 Jul 2020
Contributed by Lukas
Send a textThe Surfers focus on steps Allied Health Professions and passionate physicians can take to improve lifestyle compliance with #NASH and #NAF...
Previewing EASL: Part 1 - Ep 15
23 Jul 2020
Contributed by Lukas
Send a textFOCUS: Some of the presentations that will make NASH/NAFLD news next monthTransplant hepatologist Naim Alkhouri joins the Surfers in discus...
Respect For The Liver - Ep 14
16 Jul 2020
Contributed by Lukas
Send a textNASH is not merely a byproduct of obesity. The role the liver plays in non-liver comorbidities is complex and important. Join the Surfers a...
Diagnosing Diagnostics III: Better Tools on the Way - Ep 13
09 Jul 2020
Contributed by Lukas
Send a textFOCUS: Three sets of tools that will improve NASH disease understanding. The Surfers return to diagnostics once more. This time, they explo...
What Does “No” Mean to FDA? - Ep 12
02 Jul 2020
Contributed by Lukas
Send a textDecoding the message of Intercept’s Complete Response LetterFormer FDA Director Brian Harvey joins the Surfers to discuss what obeticholi...
Crystal Ball Tells Us the Most Important Story of the Summer - Ep 11
27 Jun 2020
Contributed by Lukas
Send a textCONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications.The Surfers discuss different elements of the evol...
Diagnosing Diagnostics II: Tools vs. Teaching - Ep 10
18 Jun 2020
Contributed by Lukas
Send a textWhat would create greater value for patients and providers?Professor Mary Rinella of Northwestern University and Suneil Hosmane of GenFit j...
International NASH Day is Here! - Ep 9
11 Jun 2020
Contributed by Lukas
Send a textSurfing the NASH Tsunami celebrates a growing and increasingly important global event for the Fatty Liver community.Global Liver Institute ...
Diagnosing Diagnostics – Part I - Ep 8
04 Jun 2020
Contributed by Lukas
Send a textRoom for improvementGenFit Head of Global Diagnostics Suneil Hosmane joins the Surfers in exploring the current strengths and drawbacks of ...
NASH-Ville - Part 2: Better Days Ahead? - Ep 7
28 May 2020
Contributed by Lukas
Send a textReviewing press releases reporting preliminary findings from six recently announced Phase 2 trialsStephen Harrison leads the Surfers, with ...
What’s in a Name: NAFLD or MAFLD? - Ep 6
21 May 2020
Contributed by Lukas
Send a textExploring the controversy over the name(s) to use when describing Fatty Liver disease(s)Professor Quentin Anstee joins the Surfers for a th...
Wild Times In NASH-Ville – Part I - Ep 5
15 May 2020
Contributed by Lukas
Send a textClinical trial results that are changing how we look at NASHStephen Harrison leads a review of two recent Phase 3 data statements: the outc...
When You Get To A Fork In The Road - Ep 4
07 May 2020
Contributed by Lukas
Send a textThree possible scenarios for development of the NASH market.Roger Green presents three possible directions for the NASH market over the nex...
C-Suite COVID-19 Challenges - Ep 3
30 Apr 2020
Contributed by Lukas
Send a textCritical considerations for companies developing NASH drugsPeter Traber focuses on ways COVID-19 can affect drug development and broader co...
Five $imple Pieces - Ep 2
23 Apr 2020
Contributed by Lukas
Send a textWhat investors want to know about NASH development during the pandemic.Yasmeen Rahimi poses five questions NASH investors ask her about the...
COVID CHAOS - Ep 1
15 Apr 2020
Contributed by Lukas
Send a textNavigating NAFLD/NASH clinical trials through the pandemicDr. Stephen Harrison discusses several ways the pandemic is affecting planning an...